a Adjusted for age, sex, BMI, race, asthma, COVPD, HF, DM,ESRD Aldosterone antagonist and steroid use.
The Kaplan-Meier curve illustrated that ACEI/ARBs were associated with increased COVID-19 mortality (Figure 3). Similarly, the unadjusted Cox proportional hazard model showed that the use of ACEI/ARBs was associated with an increase in COVID-19 mortality (HR= 1.25, 95% CI[1.01, 1.54), p-value= 0.03). However, we failed to find a statistically significant association between the history of ACEI/ARB use and 30 days-COVID-19 survival in the adjusted Cox proportional hazard model (Table 4).
Figure 3: Kaplan-Meier curve demonstrating the association between the use of ACEI/ARBS and COVID-19 mortality.